ISSN 2490-3329 (Print)
ISSN 2303-7954 (Online)

Volume 47, Issue 2, Article 9

SPECIAL  PAPER
(Scr Med 2016:47:140-147)

Drug Induced Liver Injury: Pathogenesis, Clinical Features and Monitoring

Ana Ćurguz,1 Lana Nežić,2 Danijela Mandić3

1 Division of Pharmacy, School of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina
2 Department of Pharmacology, Toxicology and Clinical Pharmacology, School of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina
3 Clinic of Internal Medicine, University Clinical Center of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina


doi:10.18575/msrs.sm.e.16.23
UDK 616.36-002:615.2
COBISS.RS-ID 6165016


ABSTRACT

Introduction: Drug-induced liver injury (DILI) is a rare but potentially life threatening adverse drug reactions. DILI may mimic pathophysiology or histopathologic features of an acute or chronic liver disease, and they may be indistinguishable from those of other causes of liver injuries. Liver can be affected directly, in a dose-dependent manner, or idiosyncratically, independently of the dose, and therefore unpredictably developed.

Methods: In this special article we provided results given in the articles published in PubMed in the period 2006-2016. The search was made based on the most frequent reported drugs inducing liver injuries, diagnostic assessment, monitoring and outcomes of DILI.

Results: The true incidence of DILI still remains unknown but the incidence of up to 14 cases per 100,000 inhabitants/year has been most frequently reported. Antimicrobial agents, analgesics, hipolipemics and antiepileptics are the most common drugs causing DILI.

Conclusion: Although several biomarkers have been found through analytical tests, none of them have been able to display enough specificity and sensitivity in DILI diagnosis. Therefore, diagnostic assessment of DILI is still based on clinical examination, pharmacological treatment history, current RUCAM criteria, and liver function laboratory test.

Key words: drugs, hepatotoxicity, idiosyncrasies, pharmacogenetics, RUCAM criteria

 

PDF version of article


Reference
1.    Björnsson E. Drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010; 32: 3-13. https://doi.org/10.1111/j.1365-2036.2010.04320.x
2.    Kim SH, Naisbitt DJ. Update on Advances in Research of Idiosyncratic Drug Induced Liver Injury. Allergy Asthma Immunol Res 2016;8:3-11. https://doi.org/10.4168/aair.2016.8.1.3
3.     Björnsson E, Olsson R. Suspected drug induced liver fatalities reported to the WHO database. Dig Liv Dis 2006;38:33-8. https://doi.org/10.1016/j.dld.2005.06.004
4.    Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatology 2015; 63:503-14.  https://doi.org/10.1016/j.jhep.2015.04.016
5.    Lewis JH, Ahmed M, Shobassy A, Palese C. Drug-induced liver disease. Curr Opin Gastroenterol 2006; 22:223-33. https://doi.org/10.1097/01.mog.0000218958.40441.fd
6.    Abboud G., Kaplowitz N. Drug-Induced Liver Injury. Drug Saf 2007; 30: 277-94. https://doi.org/10.2165/00002018-200730040-00001
7.    Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, William ML, Yuen NA et al. Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Evenets in VigiBase Drug Sad 2010;33:503-22.
8.    Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs. Swiss Med Wikly.2010; 140:w13080.
9.    Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009; 58: 1555-64. https://doi.org/10.1136/gut.2008.163675
10.    Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010;115:307–21. https://doi.org/10.1093/toxsci/kfq009
11.    Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010;51:615–20. https://doi.org/10.1002/hep.23317
12.    Suzuki A, Andrade RJ, Björnsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBaseTM. Drug Saf 2010; 33: 503-22. https://doi.org/10.2165/11535340-000000000-00000
13.    Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP,  Serrano J, et al. Standardization of Nomenclature and Causality Assessment in Drug-Induced Liver Injury: Summary of a Clinical Research Workshop. Hepatology 2010; 52: 730-42.
https://doi.org/10.1002/hep.23696
14.    Khoury T, Rmeileh AA, Yosha L, Benson AA, Daher S, Mizrahi M. Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. J Clin Transl Hepatol 2015;28:99-108.
15.    Andrade R, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced of hepatotoxicity in clinical practice: A challenge for gastroenterologists. World J Gastroenterol 2007; 13: 329-40. https://doi.org/10.3748/wjg.v13.i3.329
16.    Bessone, F.; Hernandez, N.; Lucena, M.I.; Andrade, R.J.; on behalf of the Latin DILI Network (LATINDILIN) and Spanish DILI Registry. The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. Int. J Mol. Sci 2016;17:313. https://doi.org/10.3390/ijms17030313
17.    Ou  P, Chen, Y, Li B, Zhang , Liu, X, Li F et al. Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. Springer Plus 2015;4 :802. https://doi.org/10.1186/s40064-015-1600-8
18.    Björnsson ES. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci.2015; 17, 224. https://doi.org/10.3390/ijms17020224
19.    16. Nezic L, Krähenbühl S, Rätz Bravo AE. Diclofenac induced liver injuries. Praxis (Bern 1994) 2012;101:371-9.  https://doi.org/10.1024/1661-8157/a000880
20.    Iruzubieta P, Arias-Loste MT, Barbier Torres L, Martinez Chantar ML, Crespo J. The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?.Biomed Res Int 2015;2015:386186. doi: 10.1155/2015/386186. https://doi.org/10.1155/2015/386186

 

Contact address:
Lana Nežić,
14 Save Mrkalja St,
78000 Banja Luka, Bosnia and Herzegovina
Phone: 00387 (0)51 234 100
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it


Submitted: September 13th, 2016       
Accepted: September 21st, 2016